Background
Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes.• Understanding the mechanism of IL-1β secretion., PMID:22019906• NLRP3 inflammasome mediates M1 macrophage polarization and IL-1β production in inflammatory root resorption., PMID:31976565• The role of IL-1β and TNF-α in intervertebral disc degeneration., PMID:32853910• Human Monocytes Engage an Alternative Inflammasome Pathway., PMID:27037191• D-mannose suppresses macrophage IL-1β production., PMID:33311467• BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity., PMID:29324233• Association of interleukin-6 and interleukin-1-β levels in patients with toxoplasmosis., PMID:35782407• Interleukin-1 beta is significantly upregulated in the decidua of spontaneous and recurrent miscarriage placentas., PMID:33545613• The effect of interleukin 1 beta blockade on the tumor microenvironment., PMID:33493144• Single-cell profiling identifies IL1Bhimacrophages associated with inflammation in PD-1 inhibitor-induced inflammatory arthritis., PMID:38453911